Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients.

Clinica chimica acta; international journal of clinical chemistry - 20 Mar 2014

Wang Shuai, Han Xiaohong, Hu Xingsheng, Wang Xiaoyuan, Zhao Lingdi, Tang Le, Feng Yun, Wu Di, Sun Yan, Shi Yuankai

Abstract excerpt

BACKGROUND: The use of biomarkers for selecting non-small cell lung cancer (NSCLC) patients for treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is essential. The aim of this study was to explore whether biomarkers detected in plasma were predictive for res...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Precision Medicine

Share to Protein Kinase Inhibitors

Share to Survival Analysis

Share to Transforming Growth Factor alpha

Share to Transforming Growth Factor beta1

Source

Identifiers

PMID: 24378285
DOI: 10.1016/j.cca.2013.12.026

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24378285-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients.PMID 24378285Read ↗

Plasma cell-free DNA methylation combined with tumor mutation detection in prognostic prediction of patients with non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

The prognostic role of circulating DNA markers in patients with lung malignancies: a systematic review and meta-analysis.Semantic proximity Read ↗

Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer.Semantic proximity Read ↗

Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer?Semantic proximity Read ↗

Circulating Tumor DNA Analysis in Blood for the Prediction of Treatment Response in Patientswith Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.Semantic proximity Read ↗

Clinical Implication of Monitoring Circulating Tumor DNA in Untreated Non-Small-Cell Lung Cancer PatientsSemantic proximity Read ↗

Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancerSemantic proximity Read ↗

Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage I–III non-small cell lung cancer (NSCLC) patients with baseline tissue EGFR mutationsSemantic proximity Read ↗

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs.Semantic proximity Read ↗

Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Circulating DNA: Diagnostic Tool and Predictive Marker for Overall Survival of NSCLC PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.